pharmacotherapy in acute coronary syndromes

32
Pharmacotherapy in acute coronary syndromes Perspective from first line and regional hospitals in Czech Republic Cardionale, 26.11.2010 Petr Jansky

Upload: flint

Post on 04-Jan-2016

45 views

Category:

Documents


1 download

DESCRIPTION

Pharmacotherapy in acute coronary syndromes. Perspective from first line and regional hospitals in Czech Republic. Petr Jansky. Cardionale , 26.11.2010. Pilot MI registry ( n=3188 ) 6 non PCI hospitals Discharge pharmacotherapy. Svobodová , 2008. CZECH registry. All ACS patients - PowerPoint PPT Presentation

TRANSCRIPT

Page 1: Pharmacotherapy in  acute coronary syndromes

Pharmacotherapy in acute coronary syndromes

Perspective from first line and regional hospitals in Czech Republic

Cardionale, 26.11.2010

Petr Jansky

Page 2: Pharmacotherapy in  acute coronary syndromes

Pilot MI registry (n=3188)6 non PCI hospitals

Discharge pharmacotherapy

0

10

20

30

40

50

60

70

80

90

100

2003 2004 2005 2006 2007

%

BB

ASA

statin

ACE/ARB

ticlopidin

clopidogrel

Svobodová, 2008

Page 3: Pharmacotherapy in  acute coronary syndromes

Jihočeský kraj:Č. Budějovice, Č. Krumlov, Prachatice, Strakonice, Písek, Tábor, Jindřichův Hradec, Dačice

Liberecký kraj:Č. Lípa, Liberec, Frýdlant, Jablonec n.N., Tanvald, Semily, Turnov, Jilemnice

All ACS patients11/2005N 1921

Widimský P. et al., Int J Cardiol, 2007

CZECH registry1/ all PCI hospitals (80%)2/ all community hospitals in two regions (20%)

Page 4: Pharmacotherapy in  acute coronary syndromes

Discharge pharmacotherapy STEMI

93

6682 75

848574 77

53

81

020406080

100

ASA

thie

nopyr

idin

es BB

ACEI/ARB

stat

ins

EHS ACS II 2004

CZECH registry 2005

%

Mandelzweig, EHJ, 2006 Widimský, Int J Cardiol, 2007

Page 5: Pharmacotherapy in  acute coronary syndromes

Discharge pharmacotherapy nonSTE ACS

84

56

83

58

7780

20

66

26

70

0

20

40

60

80

100

ASA

thie

nopyr

idin

es BB

ACEI/ARB

stat

ins

CZECH PCI centers CZECH non PCI

%

Widimský, Int J Cardiol, 2007

Page 6: Pharmacotherapy in  acute coronary syndromes

ESC Guidelines for the Management of NSTE-ACSESC Guidelines for the Management of NSTE-ACS

Recommendations for performance measures

Recommendations for performance measures

• Development of regional and/or national programmes to systematically measure performance indicators and provide feedback to individual hospitals is strongly encouraged (I-C).

European Heart Journal, July 2007

Page 7: Pharmacotherapy in  acute coronary syndromes

• Confirmed acute coronary syndromes (STEMI, NONSTEMI, unstable AP)• Continually since 1.7.2008• 32 non cath hospitals

Page 8: Pharmacotherapy in  acute coronary syndromes

Quality of pharmacotherapy

• Prehospital phase• Early hospital phase• On discharge

Page 9: Pharmacotherapy in  acute coronary syndromes

Patient characteristics 7/2008-3/2010

Mean age ± SD

n % STEMI % males males females

3995 27,5 60,6 66,8 ± 12,4 74,2 ± 11,0

Page 10: Pharmacotherapy in  acute coronary syndromes

Prehospital pharmacotherapy

21% 13% 3% 0% 0%6%0%

10%

20%

30%

40%

50%

ASA Clopidogrel Heparin/ LMW Heparin

BB InhibitorIIb/IIIa

Fibrinolytikum

Page 11: Pharmacotherapy in  acute coronary syndromes

Prehospital pharmacotherapyEMS vs physician

36% 9% 20% 3%10% 3% 6% 2%0%

10%

20%

30%

40%

50%

ASA Clopidogrel Heparin/ LMW Heparin

BB

p<0,001

p<0,001

p<0,001

Page 12: Pharmacotherapy in  acute coronary syndromes

Prehospital pharmacotherapy

19% 11%15% 2% 7%22%16%34% 3% 3%4% 2%0%

10%

20%

30%

40%

50%

ASA Clopidogrel Heparin/ LMW Heparin

BB

STEMI NSTEMI NAP

p<0,001

p<0,001

p<0,001

Page 13: Pharmacotherapy in  acute coronary syndromes

Evidence-based medical therapy (heparin, ASA, BB, statin, thienopyridin) within the first 24 hours after admission

is associated with lower in-hospital mortality in NSTEMI

18,8 18,3

16,3

7,1

4,4

2,1

0

2

4

6

8

10

12

14

16

18

20

0 1 2 3 4 5

Monhart et al., ESC 2008N 1889, p < 0,001

%

Page 14: Pharmacotherapy in  acute coronary syndromes

Aspirin

Linear trend: n.s.

0,8893 0,9106 0,8824 0,89250,9326

0,8837 0,9104

0%

20%

40%

60%

80%

100%

2008 III 2008 IV 2009 I 2009 II 2009 III 2009 IV 2010 I

Pharmacotherapy within 24 hours after admission

Page 15: Pharmacotherapy in  acute coronary syndromes

Betablockers

Linear trend: n.s.

Pharmacotherapy within 24 hours after admission

0,6455 0,6451 0,6614 0,66620,7260

0,6356 0,6132

0%

20%

40%

60%

80%

100%

2008 III 2008 IV 2009 I 2009 II 2009 III 2009 IV 2010 I

Page 16: Pharmacotherapy in  acute coronary syndromes

Clopidogrel

Linear trend: p=0,023

0,60940,6838

0,6330 0,65730,7116

0,6715 0,6840

0%

20%

40%

60%

80%

100%

2008 III 2008 IV 2009 I 2009 II 2009 III 2009 IV 2010 I

Pharmacotherapy within 24 hours after admission

Page 17: Pharmacotherapy in  acute coronary syndromes

Statin

Linear trend: p<0,001

0,5811

0,65340,6216

0,67280,7196

0,6647

0,7547

0%

20%

40%

60%

80%

100%

2008 III 2008 IV 2009 I 2009 II 2009 III 2009 IV 2010 I

Pharmacotherapy within 24 hours after admission

Page 18: Pharmacotherapy in  acute coronary syndromes

LMWH

Linear trend: n.s.

0,6045 0,6296 0,6286 0,64100,6005

0,6512 0,6321

0%

20%

40%

60%

80%

100%

2008 III 2008 IV 2009 I 2009 II 2009 III 2009 IV 2010 I

Pharmacotherapy within 24 hours after admission

Page 19: Pharmacotherapy in  acute coronary syndromes

Heparin

Linear trend: p=0,036

0,22290,2666 0,2647

0,2165 0,20470,1720

0,2547

0%

20%

40%

60%

80%

100%

2008 III 2008 IV 2009 I 2009 II 2009 III 2009 IV 2010 I

Pharmacotherapy within 24 hours after admission

Page 20: Pharmacotherapy in  acute coronary syndromes

Fondaparinux

Linear trend: p=0,011

0,17620,1225 0,1166

0,16410,2028 0,1924 0,1698

0%

20%

40%

60%

80%

100%

2008 III 2008 IV 2009 I 2009 II 2009 III 2009 IV 2010 I

Pharmacotherapy within 24 hours after admission

Page 21: Pharmacotherapy in  acute coronary syndromes

Pharmacotherapy within 24 hours after admission

* p<0,05; ** p<0,01; *** p<0,001

% Males Females <=70 y >70 y STEMI NSTEMI

Aspirin 90,8 88,4 92,7 87,4*** 92,9 89,7*

Clopidogrel 69,6 60,8** 74,2 58,9*** 77,4 65,4***

Heparin 25,8 19,6* 28,2 19,1*** 53,5 16,0***

LMWH 60,7 65,5 59,8 65,2 42,3 66,2***

BB 66,6 65,1 67,6 64,6* 52,1 67,7***

Fondaparinux 16,0 15,2 16,3 15,0 9,3 19,5***

ACEI 59,6 60,2 60,1 59,5 47,3 60,3***

Statin 66,6 64,1 70,2 61,6*** 53,8 65,6***

Page 22: Pharmacotherapy in  acute coronary syndromes

Aspirin

Linear trend: n.s.

0,9102 0,9359 0,9211 0,9403 0,9281 0,9222 0,9286

0%

20%

40%

60%

80%

100%

2008 III 2008 IV 2009 I 2009 II 2009 III 2009 IV 2010 I

Discharge pharmacotherapy

Page 23: Pharmacotherapy in  acute coronary syndromes

Clopidogrel

Linear trend: n.s.

0,6626 0,695 0,69270,7343 0,7104

0,6570,7286

0%

20%

40%

60%

80%

100%

2008 III 2008 IV 2009 I 2009 II 2009 III 2009 IV 2010 I

Discharge pharmacotherapy

Page 24: Pharmacotherapy in  acute coronary syndromes

Clopidogrel on discharge – individual hospitals

0

10

20

30

40

50

60

70

80

90

100

%

Page 25: Pharmacotherapy in  acute coronary syndromes

Betablockers

Linear trend: n.s.

0,8364 0,81990,857 0,8345

0,8854 0,86340,819

0%

20%

40%

60%

80%

100%

2008 III 2008 IV 2009 I 2009 II 2009 III 2009 IV 2010 I

Discharge pharmacotherapy

Page 26: Pharmacotherapy in  acute coronary syndromes

Betablockers on discharge – individual hospitals

0

10

20

30

40

50

60

70

80

90

100

%

Page 27: Pharmacotherapy in  acute coronary syndromes

ACEI

Linear trend: p=0,012

0,76530,7311

0,815 0,819 0,8014 0,77550,823

0%

20%

40%

60%

80%

100%

2008 III 2008 IV 2009 I 2009 II 2009 III 2009 IV 2010 I

Discharge pharmacotherapy

Page 28: Pharmacotherapy in  acute coronary syndromes

Statin

Linear trend: p<0,001

0,832 0,84790,8826 0,8967 0,9007 0,9038

0,9372

0%

20%

40%

60%

80%

100%

2008 III 2008 IV 2009 I 2009 II 2009 III 2009 IV 2010 I

Discharge pharmacotherapy

Page 29: Pharmacotherapy in  acute coronary syndromes

Combination (aspirin, clopidogrel, BB, ACEI, statin)

Linear trend: p=0,010

0,4283 0,42050,4707

0,5164 0,51940,4415

0,4854

0%

20%

40%

60%

80%

100%

2008 III 2008 IV 2009 I 2009 II 2009 III 2009 IV 2010 I

Discharge pharmacotherapy

Page 30: Pharmacotherapy in  acute coronary syndromes

Discharge pharmacotherapy

% Males Females <=70 y >70 y STEMI NSTEMI

Aspirin 93,5 91,6 95,6 89,9*** 96,6 92,5***

Clopidogrel 74,2 62,9*** 78,5 60,9*** 87,3 71,6***

BB 85,2 83,4 86,0 83,0* 86,1 84,0

ACEI 79,8 77,6 79,9 78,1 82,3 77,0**

Statin 89,7 85,4 92,3 83,6*** 91,4 85,7**

* p<0,05; ** p<0,01; *** p<0,001

Page 31: Pharmacotherapy in  acute coronary syndromes

Conclusion

• Unsatisfactory prehospital pharmacotherapy • In-hospital pharmacotherapy is relatively good

(exc. elderly, females, NONSTEMI)• Interhospital variability in the quality of care• Improvement in some recommended therapies

(statins, clopidogrel in the acute phase) over short time period

Page 32: Pharmacotherapy in  acute coronary syndromes

Thank you for your attention !